Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week.
Activity was light, although news on clinical trial readouts continued to flow.
The following are catalytic events that could impact biotech stocks in the unfolding week:
14th Euro-Global Gastroenterology Conference: July 8-9 in Zurich, Switzerland.
Clinical Trial Readouts
Intra-Cellular Therapies Inc (NASDAQ: ITCI) is scheduled to release top-line data from a Phase 3 study dubbed 401 that is evaluating its ITI-007 as a monotherapy for bipolar depression.
The company will also release top-line data from another late-stage study dubbed 404 that is evaluating ITI-007 as a monotherapy for bipolar depression.
AngioDynamics, Inc. (NASDAQ: ANGO): Wednesday, July 10 before the market open.
Credit Suisse: United Therapeutics Becoming More Fundamentally Driven
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
See more from Benzinga
- The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
- The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief
- The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.